WDAY — Workday, Inc.

The market is split rather than decisively negative. Workday beat on Aug 27, 2026 (Q2 FY2027 revenue $2.65B, +13% YoY; non-GAAP EPS $2.75 vs. $2.61 consensus; subscription revenue +14%), but guided Q3 subscription revenue to ~$2.515B (+12%) and cRPO growth to 11-12% against Street expectations near 14% - a backlog deceleration the market punished, with the stock down 5.15% in the week into 2026-09-13. Offsetting that: a new $4B open-ended buyback (announced alongside results, after the prior $5B program was completed six months early), AI ARR of ~$600M growing >200% YoY with >$100M of new AI ACV in Q2, and >5,500 customers using native AI agents. Analyst consensus sits at Buy with a $204-209 target range, implying modest upside - so sentiment reads as 'constructive but no longer paying up,' which is why three-month momentum (+41.97%) is colliding with a single-week pullback.

Revenue growth has clearly decelerated from the mid-teens of FY2025 to a plateau: +15.8% (Oct 2025 quarter), +15.0% (Jan 2025), then +12.6%, +12.6%, +12.6%, +14.5%, +13.5%, +12.9% across the last six quarters. Importantly, this is now a plateau between 12.5% and 14.5%, not continued deceleration - the biggest single step down already happened in fiscal 2025. Gross margin is remarkably stable, 75.2-76.2% every quarter for three years. The real story is GAAP operating margin: from ~4.1%/4.7% in FY2024 quarters to 10.6% (Q2 FY2026), 12.0% (Q4 FY2026), 13.3% (Q1 FY2027) and 12.0% (Q2 FY2027) - roughly a tripling of operating margin in three years, with TTM operating income of $1,218M on $10,157M of revenue (12.0%). Reported net income is noisy and not a clean trend: $118.8M in Q4 FY2024 (distorted by the $4.42 diluted EPS tax benefit), $68M in Q1 FY2026 (a low-margin quarter with a $39M operating profit), and $632M / $2.57 EPS in Q2 FY2027 - a quarter where net income far exceeded operating income of $317M, pointing to a large below-the-line/tax item rather than operating strength. Watch Q2 FY2027 operating cash flow of $520M, down 15.6% YoY from $616M, even as TTM OCF rose ~19% to $3,082M - one soft quarter, but a genuine yellow flag in an otherwise clean FCF record.

As of 2026-09-13, at $185.70 the headline TTM P/E of 37.5x is misleading - TTM EPS of $5.015 is inflated by one-off tax items (the $2.57 quarter in Q2 FY2027 and the $4.42 quarter back in Q4 FY2024). The more honest framing is the forward number: against consensus next-FY EPS of $11.072, the stock trades at ~16.8x forward earnings, with a reported PEG of 0.298. P/S of 4.79x versus a 5-year average of 8.62x is a deep discount to its own history, and the deterministic framework flags it 'Cheap vs. its own history.' On the other side, EV/EBITDA of 29.7x (on ~$1.6B of TTM EBITDA) and P/B of 7.17x are not cheap in absolute terms, ROIC of 5.9% is low, and a 5.85% TTM FCF yield ($2.84B FCF on a $48.6B cap) looks generous only until you net out heavy stock-based compensation, which runs well north of $1.5B annually. Net: cheap versus its own history and cheap on forward non-GAAP earnings for a 75%-gross-margin, low-double-digit grower, but not cheap on GAAP economics once SBC is treated honestly. 'Average 5-year P/E of 590.9x' is a data artifact from near-zero earnings years and should be ignored entirely.

The market is pricing Workday off forward non-GAAP EPS (~$11.07 at ~17x), not off the noisy GAAP TTM. That is a low multiple for this quality/growth profile, and it effectively says the market believes the cRPO deceleration to 11-12% is the new ceiling, or worse. That creates an asymmetric setup around the late-November Q3 print: cRPO stabilizing at 12%+ with subscription revenue holding ~12-13% likely re-rates the multiple toward 19-21x (~$210-230), while cRPO slipping below 11% likely compresses it to 15-16x (~$166-177, back toward the 50-day/200-day support zone). Note two mechanical supports the P/E doesn't advertise: the $4B buyback is roughly 8% of market cap and shrinks the share count that the EPS denominator is built on, and margin expansion (operating margin nearly tripling in three years) means EPS should grow faster than revenue even if growth doesn't reaccelerate. Do not read the 37.5x TTM P/E as 'expensive' - it is an artifact of one-time tax benefits, not a deterioration or a premium.

As of 2026-09-13, RSI stood at 49.42 - dead neutral, neither overbought nor oversold after a 41.97% three-month and 39.53% six-month rally. The stock is 4.8% below its 20-day SMA but 8.82% above its 50-day and 16.47% above its 200-day, which is the classic signature of an intact uptrend digesting a post-earnings gap down rather than a broken chart. The 1-week return of -5.15% against a 1-month +5.94% says the pullback is days old, not months old. Timing implication: this is not a chase point and not a capitulation point. A constructive entry would be on stabilization near the 50-day SMA (roughly the $170-175 area, which is also near the post-earnings reaction low); a break below the 200-day would invalidate the trend and argue for standing aside until the late-November Q3 print.

• Enterprise software budget scrutiny and elongated sales cycles - the direct cause of the cRPO guidance cut to 11-12%; large-deal timing, not churn, is what is moving the backlog number.
• AI monetization expectations are now a valuation input, not a side story: Workday's ~$600M AI ARR (+200%+ YoY) and >5,500 AI-agent customers help, but the market wants proof AI SKUs are incremental ACV rather than a repackaging of existing subscription dollars.
• Discount rates / duration sensitivity - a ~$49B-cap, high-gross-margin software name with an active buyback is sensitive to rate moves; falling rates would help the multiple, rising rates would compound the growth-deceleration concern.
• Public-sector offset - state and local government wins (Akron, State of Georgia) are partially cushioning weak private-sector tech budgets, and government demand tends to be less cyclical than enterprise.
• Competitive intensity - Microsoft, Oracle, SAP and ADP bundling, plus AI-native HR/finance startups, keep pricing power in check even at 75% gross margins.

• Financial Analyst Day on October 13, 2026 - management is expected to reset long-term margin targets and lay out the agentic-AI monetization roadmap; this is the single biggest scheduled event that could re-rate the multiple.
• Q3 FY2027 earnings in late November 2026 (historically around Nov 24) - the decisive test of whether cRPO growth stabilizes at the guided 11-12% or keeps sliding.
• Execution on the new $4B buyback authorized on Aug 27, 2026 (~8% of market cap) - mechanically supports EPS and signals management's view that the stock is undervalued.
• Scaling of AI products beyond the ~$600M ARR run-rate, including attach rates on new AI SKUs and the >$100M quarterly AI ACV pace.
• Continued public-sector and large-enterprise displacement wins against legacy on-premise systems.

• cRPO growth of 11-12% is the leading indicator for subscription revenue - if it settles at or below 11%, the business is a ~10% grower, not a 13% one, and the forward multiple compresses hard.
• Earnings quality: GAAP net income is distorted by one-off tax benefits in both Q4 FY2024 ($4.42 EPS) and Q2 FY2027 ($2.57 EPS), and stock-based compensation runs well above $1.5B annually - the $2.84B TTM FCF headline is materially less impressive once SBC is treated as a real cost.
• Balance-sheet erosion from aggressive capital return: cash fell from $2,609M (Oct 2025) to $661M (Jul 2026), stockholders' equity fell from $8,879M to $6,460M, and the current ratio is 0.908 - below 1. Little cushion if growth disappoints further.
• Operating cash flow declined 15.6% YoY in Q2 FY2027 ($520M vs. $616M) despite 13% revenue growth - if this is a trend rather than one quarter, the cash-generation narrative weakens.
• Competitive and platform risk: AI-native entrants and mega-vendor bundling (Microsoft, Oracle, SAP) could pressure pricing and win rates precisely as the company argues AI is additive.

Workday is a genuinely high-quality franchise - 75%+ gross margins, nearly $10.2B in TTM revenue, $2.84B in TTM free cash flow, and a GAAP operating margin that has gone from ~4% to 12% in three years - trading at about 16.8x forward non-GAAP EPS and 4.79x sales versus a five-year average P/S of 8.62x. That is a real discount, and the $4B buyback plus AI ARR growing triple digits are tangible positives. The problem is that the market has priced this as a decelerating story for good reason: cRPO growth guided to 11-12% against ~14% expected, subscription growth slowing to 12%, and cash flow weakness in the most recent quarter. My read is that the stock is reasonably, not attractively, priced: you are paid to wait through the Analyst Day (Oct 13, 2026) and the Q3 print (late Nov 2026), but there is no evident catalyst forcing an immediate re-rate, and the earnings quality (SBC-heavy, one-off-boosted) argues against underwriting an aggressive multiple. This is a hold/accumulate-on-weakness name, not a buy-the-breakout name.

Blended three approaches as of 2026-09-13: (1) 19x my forward non-GAAP EPS estimate of $11.072 (a discount to the median software multiple to reflect 12-13% growth and SBC-heavy margins) = $210; (2) 5.4x TTM revenue of $10,157M - a premium to the current 4.79x but a steep discount to the five-year average P/S of 8.62x - on 261.9M shares = $209; (3) a 5.0% required FCF yield on $2,844M of TTM free cash flow = $217. Weighting these 50/30/20 gives roughly $211, rounded down to $210 to reflect the cRPO deceleration to 11-12% that the trailing multiples do not capture.